Oral GLP-1 Medication and Weight Loss in Menopausal Women

Orforglipron Produced Similar Weight Reductions Across Menopause Groups

Daily oral orforglipron produced similar weight loss of up to 14 percent in women before, during, and after menopause in two 72-week clinical trials. The findings come from a subgroup analysis presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan, Italy. Eli Lilly and Company evaluated the drug in female participants across three reproductive stages.

Estrogen deficiency during menopause often complicates weight management by shifting body fat distribution. Orforglipron is an oral small-molecule, nonpeptide Glucagon-Like Peptide-1 (GLP-1) receptor agonist designed for daily administration. The trial evaluated whether changing reproductive hormone status altered how well the drug reduced body weight.

The Analysis Evaluated Overweight and Obese Women in the ATTAIN Trials

The study combined female participants from the ATTAIN-1 and ATTAIN-2 clinical trials who had overweight or obesity. ATTAIN-1 enrolled people without diabetes, while ATTAIN-2 evaluated individuals diagnosed with type 2 diabetes. Participants met a baseline Body Mass Index (BMI) of at least 30 kilograms per square meter, or at least 27 kilograms per square meter with a weight-related medical condition.

Investigators separated the participants into premenopausal, perimenopausal, and postmenopausal categories. The number of women in each category receiving orforglipron or a placebo ranged from 142 to 225. Researchers monitored weight changes over 72 weeks of daily oral treatment.

Waist Measurements Decreased Along With Total Body Weight

Women taking orforglipron lost up to 12.5 centimeters, or 4.9 inches, of waist circumference over 72 weeks. These waist reductions occurred consistently across all three menopausal stages in both trials. A higher proportion of treated women moved into lower waist-to-height ratio categories compared to those on placebo.

Threshold analyses showed measurable differences in response rates between active medication and inactive treatment:

• Up to 83 percent of women receiving orforglipron lost at least 5 percent of their baseline body weight.
• Only 30 percent of women receiving placebo reached that same 5 percent weight reduction threshold.
• Participants on orforglipron reached higher weight loss thresholds of 10 percent, 15 percent, and 20 percent more frequently than placebo recipients.

Study Sponsorship and Trial Structure Present Clear Limitations

Lead author Dr. Hunter Thomas Hoffman and colleagues conducted this research as employees of Eli Lilly and Company, the pharmaceutical manufacturer developing orforglipron. Subgroup analyses carry inherent statistical limitations because the trials were not primarily powered around menopausal status. The presented results represent conference findings that have not yet undergone full peer-reviewed journal publication.

Orforglipron remains an investigational medication that has not received regulatory approval from the United States Food and Drug Administration (FDA) or European agencies. Patients managing weight during menopausal transitions should discuss approved therapeutic options and metabolic health strategies with their clinician.